JUNE 3, 2024 by Case Western Reserve University Credit: Pixabay/CC0 Public DomainA new study by researchers at the Case Western Reserve University School of Medicine reveals that the popular diabetes and weight-loss drugs Wegovy and Ozempic are linked to reduced incidence and recurrence of alcohol abuse or dependence. The team’s findings, recently published in the...
by Elana Gotkine For patients with type 2 diabetes mellitus, most eyes have no worsening of diabetic retinopathy (DR) after initiation of semaglutide, according to a study presented at the annual meeting of the American Academy of Ophthalmology, held from Nov. 3 to 6 in San Francisco. Zeeshan Haq, M.D., from Retina Consultants of Minnesota...
Marlene Busko October 31, 2023 With nutrient-stimulated hormone therapies for obesity in phase 3 trials, and activin-receptor inhibitors the next upcoming drug class, highly effective treatments for obesity are on the horizon. “We are at a watershed [moment] brought on by the recent introduction of highly effective antiobesity medications,” said Ania M. Jastreboff, MD, PhD, in a...
Katherine Lewin | News Reporter Novo Nordisk’s GLP-1 Wegovy has shown cardiovascular benefit again, this time in the Phase III STEP HFpEF trial, on top of the expected weight loss, the company announced at the European Society of Cardiology (ESC) Congress today. Against placebo, 2.4 mg of Wegovy (semaglutide) showed “large” reductions in heart failure-related...
Beth Snyder BulikSenior EditorAs fatty liver disease gets a new name, will it also finally get approved drug treatments? That’s what healthcare professionals are hoping for as nonalcoholic fatty liver disease (NAFLD) becomes metabolic dysfunction-associated fatty liver disease (MAFLD), and nonalcoholic steatohepatitis (NASH) becomes metabolic dysfunction-associated steatohepatitis (MASH). The name changes, aimed at getting rid...
June 25, 2023 10:39 PM EDTUpdated 05:32 AM R&DNovo Nordisk’s oral semaglutide on par with injectable version in weight loss and safetyKatherine LewinNews ReporterAn oral version of Novo Nordisk’s semaglutide helped patients taking the highest dose lose 15% of their body weight, the company reported in a new update. It’s on par with Novo’s Wegovy,...
by Margaret Steele, The Conversation The drug in Wegovy was inspired by the venom of the endangered Gila monster. Credit: Kunal Mehta/Shutterstock A few years ago, celebrity weight-control practices were out of most people’s reach. Live-in chefs and personal trainers, not to mention elaborate surgical procedures like the Brazilian butt lift, were not real options for...
Marlene Busko June 13, 2023 Could glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide — approved as Ozempic to treat type 2 diabetes and as Wegovy to treat obesity, both from Novo Nordisk — also curb addictions and compulsive behaviors? As demand for semaglutide for weight loss grew following approval of Wegovy by the US Food and Drug Administration in 2021, anecdotal reports of...
A late-breaking abstract was released today on a study in which patients were given a higher dose (2.4 mg) of semaglutide than is currently approved for weight management. Semaglutide, a GLP-1 analog drug approved at a higher dose (2mg) in March for type 2 diabetes, only received approval to treat obesity last year. In the STEP 1 trial, 1,961...
(HealthDay)—Among adults with overweight or obesity, once-weekly subcutaneous semaglutide plus counseling for diet and physical activity results in significantly greater weight loss at 68 weeks than once-daily subcutaneous liraglutide, according to a study published in the Jan. 11 issue of the Journal of the American Medical Association. Domenica M. Rubino, M.D., from the Washington Center for...
